Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 2
1990 1
1991 3
1992 2
1994 3
1995 1
1996 1
1997 3
1998 3
2000 1
2001 4
2002 3
2003 1
2004 3
2005 2
2006 4
2007 2
2008 4
2010 6
2011 4
2012 9
2013 4
2014 3
2015 2
2016 2
2017 6
2018 6
2019 5
2020 5
2021 3
2022 5
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for line janson
Search for Liene Jansone instead (1 results)
Combination chemotherapy in advanced adrenocortical carcinoma.
Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la Fouchardière C, Schlumberger M, Mantero F, Weismann D, Beuschlein F, Gelderblom H, Wilmink H, Sender M, Edgerly M, Kenn W, Fojo T, Müller HH, Skogseid B; FIRM-ACT Study Group. Fassnacht M, et al. N Engl J Med. 2012 Jun 7;366(23):2189-97. doi: 10.1056/NEJMoa1200966. Epub 2012 May 2. N Engl J Med. 2012. PMID: 22551107 Free article. Clinical Trial.
Among the 185 patients who received the alternative regimen as second-line therapy, the median duration of progression-free survival was 5.6 months in the EDP-mitotane group and 2.2 months in the streptozocin-mitotane group. Patients who did not receive the alternative sec …
Among the 185 patients who received the alternative regimen as second-line therapy, the median duration of progression-free survival …
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study.
Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U. Sorbye H, et al. Ann Oncol. 2013 Jan;24(1):152-60. doi: 10.1093/annonc/mds276. Epub 2012 Sep 11. Ann Oncol. 2013. PMID: 22967994 Free article.
RESULTS: The median survival was 11 months in 252 patients given palliative chemotherapy and 1 month in 53 patients receiving best supportive care (BSC) only. The response rate to first-line chemotherapy was 31% and 33% had stable disease. Ki-67<55% was by receiver oper …
RESULTS: The median survival was 11 months in 252 patients given palliative chemotherapy and 1 month in 53 patients receiving best supportiv …
Bivalent EGFR-Targeting DARPin-MMAE Conjugates.
Karsten L, Janson N, Le Joncour V, Alam S, Müller B, Tanjore Ramanathan J, Laakkonen P, Sewald N, Müller KM. Karsten L, et al. Int J Mol Sci. 2022 Feb 23;23(5):2468. doi: 10.3390/ijms23052468. Int J Mol Sci. 2022. PMID: 35269611 Free PMC article.
Bringing asthma care into the twenty-first century.
Larsson K, Kankaanranta H, Janson C, Lehtimäki L, Ställberg B, Løkke A, Høines K, Roslind K, Ulrik CS. Larsson K, et al. NPJ Prim Care Respir Med. 2020 Jun 5;30(1):25. doi: 10.1038/s41533-020-0182-2. NPJ Prim Care Respir Med. 2020. PMID: 32503985 Free PMC article. Review.
In this review, we address the key issues of asthma diagnosis and management, recent evidence for levels of asthma control, the consequences of poor control and, in line with that, explore the potential reasons for poor asthma control and acute exacerbations. ...
In this review, we address the key issues of asthma diagnosis and management, recent evidence for levels of asthma control, the consequences …
Drug concentration at the site of disease in children with pulmonary tuberculosis.
Lopez-Varela E, Abulfathi AA, Strydom N, Goussard P, van Wyk AC, Demers AM, Deventer AV, Garcia-Prats AJ, van der Merwe J, Zimmerman M, Carter CL, Janson J, Morrison J, Reuter H, Decloedt EH, Seddon JA, Svensson EM, Warren R, Savic RM, Dartois V, Hesseling AC. Lopez-Varela E, et al. J Antimicrob Chemother. 2022 May 29;77(6):1710-1719. doi: 10.1093/jac/dkac103. J Antimicrob Chemother. 2022. PMID: 35468189 Free PMC article.
BACKGROUND: Current TB treatment for children is not optimized to provide adequate drug levels in TB lesions. Dose optimization of first-line antituberculosis drugs to increase exposure at the site of disease could facilitate more optimal treatment and future treatment-sho …
BACKGROUND: Current TB treatment for children is not optimized to provide adequate drug levels in TB lesions. Dose optimization of first- …
Target gene regulatory network of miR-497 in angiosarcoma.
Benton A, Terwilliger E, Moriarty NM, Liu B, Murphy A, Maluvac H, Shu M, Gartenhaus LE, Janson ND, Pfeffer CM, Utturkar SM, Parkinson EI, Lanman NA, Hanna JA. Benton A, et al. bioRxiv [Preprint]. 2023 Sep 25:2023.09.24.559218. doi: 10.1101/2023.09.24.559218. bioRxiv. 2023. PMID: 37808715 Free PMC article. Updated. Preprint.
To understand the mechanism of miR-497 in tumor suppression, we identified clinically relevant target genes using a combination of RNA-sequencing data in an AS cell line, expression data from AS patients, and target prediction algorithms. ...
To understand the mechanism of miR-497 in tumor suppression, we identified clinically relevant target genes using a combination of RNA-seque …
miR-497 target gene regulatory network in angiosarcoma.
Benton A, Moriarty NM, Terwilliger E, Liu B, Murphy A, Maluvac H, Shu M, Gartenhaus LE, Janson ND, Pfeffer CM, Utturkar SM, Parkinson EI, Lanman NA, Hanna JA. Benton A, et al. Mol Cancer Res. 2024 May 21. doi: 10.1158/1541-7786.MCR-23-1075. Online ahead of print. Mol Cancer Res. 2024. PMID: 38771248
To understand the mechanism of miR-497 in tumor suppression, we identified clinically relevant target genes using a combination of RNA-sequencing data in an angiosarcoma cell line, expression data from angiosarcoma patients, and target prediction algorithms. ...
To understand the mechanism of miR-497 in tumor suppression, we identified clinically relevant target genes using a combination of RNA-seque …
A novel germline mutation in CDK4 codon 24 associated to familial melanoma.
Bottillo I, La Starza R, Radio FC, Molica C, Pedace L, Pierini T, De Bernardo C, Stingeni L, Bargiacchi S, Paiardini A, Janson G, Mecucci C, Grammatico P. Bottillo I, et al. Clin Genet. 2018 Apr;93(4):934-935. doi: 10.1111/cge.13129. Epub 2017 Nov 10. Clin Genet. 2018. PMID: 29124743 No abstract available.
A new instrument to clinically evaluate the anteroposterior relationship of the maxillary central incisors to the forehead.
Rodriguez-Tarma ZA, Estrada-Vitorino MA, Carruitero MJ, Portocarrero-Reyes W, Castillo AA, Flores-Mir C, Janson G. Rodriguez-Tarma ZA, et al. J World Fed Orthod. 2022 Oct;11(5):176-180. doi: 10.1016/j.ejwf.2022.07.001. Epub 2022 Aug 5. J World Fed Orthod. 2022. PMID: 35934619
Measurements were performed according to Element II of the Andrews' Six Elements of Orofacial Harmony by assessing the horizontal distance between the facial axis point of the maxillary central incisor and the forehead's anterior limit line. The instrument tested was a tra …
Measurements were performed according to Element II of the Andrews' Six Elements of Orofacial Harmony by assessing the horizontal distance b …
95 results